the prognostic value of ctdna in nsclc treated with neoadjuvant chemoimmunotherapy
Published 3 years ago • 148 plays • Length 6:55Download video MP4
Download video MP3
Similar videos
-
3:29
ctdna and cfdna : prognostic value in the neoadjuvant setting of colon cancer
-
1:21
nadim: baseline ctdna as a prognostic factor for pfs
-
1:29
biomarker identification in nsclc treated with neoadjuvant chemo-io
-
3:43
evolving applications of ctdna in lung cancer: mrd, early detection, and molecular profiling
-
1:49
ctdna ngs for treatment decision-making in nsclc
-
1:25
neoadjuvant therapy is taking off in lung cancer
-
3:06
the application of liquid biopsy ctdna analysis in nsclc
-
3:44
ctdna as a diagnostic, prognostic, and predictive biomarker for lung cancer
-
3:30
ctdna as an mrd biomarker for nsclc
-
1:41
recent developments in the treatment of nsclc
-
6:22
utilising ctdna in oncology
-
2:07
checkmate 816: addressing unanswered questions on surgical outcomes following neoadjuvant chemo-io
-
3:00
liquid biopsy: future directions for ctdna in nsclc
-
3:28
the future of nsclc treatment
-
1:51
future directions for neoadjuvant immunotherapy in lung cancer
-
3:07
future uses of ctdna measurements: changing the treatment landscape
-
4:26
the reproducibility of decision-making at a mtb for treatment strategies of stage iiia nsclc
-
27:03
triple negative breast cancer: predictive and prognostic biomarkers for neo/adjuvant therapy
-
3:16
perioperative therapies in nsclc